Resource Materials
Each year, thousands of people are treated for the pain associated with a vertebral compression fracture (VCF). The majority of fractures are treated using a 25 year old technology called polymethylmethacrylate (PMMA). Now physicians can use Cortoss™ Bone Augmentation Material, a new synthetic material that provides structural support, reduces pain, and restores function.
When injected, Cortoss flows around the trabecular bone in your spine, conforming to the natural framework. Then, by forming a direct bond with the existing host bone, Cortoss provides a more physiologic and therapeutic strengthening of the framework.
Why Cortoss is the right choice for VCF repair:
- Offers the strength and durability of healthy natural bone
- Creates a surface that is favorable to new bone formation and attachment
- Enables the patient to be weight bearing in as little as 15 minutes post-procedure
- Improves short-term pain relief and long-term functional outcomes1
- Reduces incidence of new fracture at adjacent levels1,2
1. As compared to polymethylmethacrylate in a blinded, randomized, prospective study.
2. In patients with one level treated and no previous fracture.
Cortoss™ Bone Augmentation Material is a composite material that functions as a strengthening agent for injection into vertebral bodies with compression fractures or weakened bone stock. Cortoss is indicated for the fixation of pathological frac¬tures of the vertebral body using vertebral augmentation. Painful vertebral com¬pression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancers, myeloma). As with any bone augmentation material, the most common complications include leakage outside of the vertebral body, adjacent level fractures, and pain. Please speak with your physician for a complete description of the risks associated with this material.